全文获取类型
收费全文 | 215023篇 |
免费 | 2979篇 |
国内免费 | 182篇 |
专业分类
耳鼻咽喉 | 1425篇 |
儿科学 | 7258篇 |
妇产科学 | 3453篇 |
基础医学 | 21807篇 |
口腔科学 | 2604篇 |
临床医学 | 14992篇 |
内科学 | 40965篇 |
皮肤病学 | 1580篇 |
神经病学 | 19221篇 |
特种医学 | 10376篇 |
外科学 | 35286篇 |
综合类 | 2462篇 |
一般理论 | 1篇 |
预防医学 | 19384篇 |
眼科学 | 3531篇 |
药学 | 12213篇 |
中国医学 | 706篇 |
肿瘤学 | 20920篇 |
出版年
2023年 | 170篇 |
2022年 | 319篇 |
2021年 | 815篇 |
2020年 | 395篇 |
2019年 | 566篇 |
2018年 | 22506篇 |
2017年 | 17834篇 |
2016年 | 20074篇 |
2015年 | 1627篇 |
2014年 | 1757篇 |
2013年 | 1923篇 |
2012年 | 8749篇 |
2011年 | 22927篇 |
2010年 | 19879篇 |
2009年 | 12465篇 |
2008年 | 21187篇 |
2007年 | 23516篇 |
2006年 | 2596篇 |
2005年 | 4192篇 |
2004年 | 5296篇 |
2003年 | 6321篇 |
2002年 | 4540篇 |
2001年 | 1774篇 |
2000年 | 1897篇 |
1999年 | 1485篇 |
1998年 | 750篇 |
1997年 | 621篇 |
1996年 | 474篇 |
1995年 | 422篇 |
1994年 | 393篇 |
1993年 | 366篇 |
1992年 | 985篇 |
1991年 | 926篇 |
1990年 | 878篇 |
1989年 | 838篇 |
1988年 | 743篇 |
1987年 | 750篇 |
1986年 | 633篇 |
1985年 | 607篇 |
1984年 | 397篇 |
1983年 | 341篇 |
1982年 | 187篇 |
1980年 | 167篇 |
1979年 | 246篇 |
1978年 | 193篇 |
1974年 | 180篇 |
1973年 | 170篇 |
1970年 | 171篇 |
1969年 | 175篇 |
1968年 | 165篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
101.
Antonio Gómez Mercedes Salgado Manuel Valladares-Ayerbes Mónica Jorge Ana Carballo Sonia Candamio Pilar Izquierdo Paula Peleteiro Rafael López 《Clinical & translational oncology》2010,12(12):843-848
Objective
The aim of the project was to assess the effectiveness and safety of weekly epoetin-beta (EB) in patients with gastrointestinal cancer (GIC) subjected to concomitant chemoradiotherapy (CCTRT). 相似文献102.
Seppo W. Langer 《Current oncology reports》2010,12(4):242-246
Extravasation of chemotherapy is a feared complication of anticancer therapy. The accidental leakage of cytostatic agents
into the perivascular tissues may have devastating short-term and long-term consequences for patients. In recent years, the
increased focus on chemotherapy extravasation has led to the development of international guidelines that have proven useful
tools in daily clinical practice. Moreover, the tissue destruction in one of the most dreaded types of extravasation (ie,
anthracycline extravasation) now can effectively be prevented with a specific antidote, dexrazoxane. 相似文献
103.
Carlos Ferrer Albiach Antonio Conde Moreno Marta Rodríguez Cordón Virginia Morillo Macías Ana Bouché Babiloni Inmaculada Beato Tortajada Ángel Sánchez Iglesias Alicia Francés Muñoz 《Clinical & translational oncology》2010,12(1):22-26
Hypoxia is related to poor prognosis because it is associated to chemo-and radioresistance. During recent years the evolution
of imaging methods like PET/CT and MRI has meant the appearance of new perspectives with direct implications in radiation
therapy. We discuss previous experiences in staging, planning and in the follow-up process with these techniques for measuring
tumour hypoxia. 相似文献
104.
Lidong Zhang James E Littlejohn Yu Cui Xiaobo Cao Chander Peddaboina W Roy Smythe 《Molecular cancer》2010,9(1):110
Background
Bortezomib, a proteasome-specific inhibitor, has emerged as a promising cancer therapeutic agent. However, development of resistance to bortezomib may pose a challenge to effective anticancer therapy. Therefore, characterization of cellular mechanisms involved in bortezomib resistance and development of effective strategies to overcome this resistance represent important steps in the advancement of bortezomib-mediated cancer therapy. 相似文献105.
Background
The fibromyalgia syndrome (FMS) is suggested to be a manifestation of depression or affective spectrum disorder. We measured the cognitive style of patients with FMS to assess personality styles in 44 patients with fibromyalgia syndrome (FMS) by comparing them with 43 patients with major depressive disorder (MDD) and 41 healthy controls (HC). 相似文献106.
107.
Keisuke Mitsuoka Sosuke Miyoshi Yukio Kato Yoshihiro Murakami Rie Utsumi Yoshiyuki Kubo Akihiro Noda Yukio Nakamura Shintaro Nishimura Akira Tsuji 《Journal of nuclear medicine》2008,49(4):615-622
H+/peptide transporter, PEPT1, is functionally expressed in some human cancer cell lines and might be a candidate molecular target for detection of cancers in vivo using PET. The aim of the present study was to establish a novel tumor-imaging technology using a PET tracer targeted to H+/peptide transporter(s). We also compared the tracer with 18F-FDG, focusing on the specificity of their accumulation between tumor and inflammatory tissues. METHODS: A dipeptide PET tracer, 11C-glycylsarcosine (11C-Gly-Sar), was injected intravenously into athymic mice transplanted with human pancreatic, prostate, and gastric cancer cells. The distribution patterns of 11C-Gly-Sar and 18F-FDG in the tumor-bearing mice, and in mice with inflammatory tissue, were assessed by imaging with a positron planar imaging system (PPIS). Tissue distributions of tracer radioactivity were also measured. The expression levels of PEPT1 and PEPT2 (PEPTs) proteins in tumor xenografts and inflammatory tissue were examined by immunohistochemical analysis. The messenger RNA expression levels of PEPTs in 58 available cancer cell lines were quantified by means of real-time polymerase chain reaction. RESULTS: All 3 tumor xenografts were well visualized with the PPIS after injection of 11C-Gly-Sar. Expression of PEPTs in those xenografts was confirmed by immunohistochemical analysis. Tumor-to-blood concentration ratios of 11C-Gly-Sar increased in a time-dependent manner and were much higher than unity. Most of the radioactivity found in the tumor tissue was recovered as the intact tracer. These results indicated that 11C-Gly-Sar was taken up by the PEPTs in tumor xenografts. It is noteworthy that 11C-Gly-Sar was minimally present in inflammatory tissues that expressed no PEPT1 or PEPT2 protein, whereas 18F-FDG was highly accumulated, with the values of the selectivity index being >25.1 and 0.72 for 11C-Gly-Sar and 18F-FDG, respectively. The mRNAs of PEPT1 and PEPT2 were expressed in 27.6% and 93.1%, respectively, of the cancer cell lines examined in the present study. CONCLUSION: The present study indicates that 11C-Gly-Sar is a promising tumor-imaging agent and is superior to 18F-FDG for distinguishing between tumors and inflammatory tissue. Because PEPTs were ubiquitously expressed in various types of tumor cells examined, 11C-Gly-Sar could be useful for the detection of many types of cancers. 相似文献
108.
109.
Kimberly A. Varker Edward W. Martin Dori Klemanski Bryan Palmer Manisha H. Shah Mark Bloomston 《Journal of gastrointestinal surgery》2007,11(12):1680-1685
Background
Transarterial chemoemobolization (TACE) is commonly used to treat metastatic carcinoid tumors; however, the management of
progressive disease is less clear. We sought to determine if patients with disease progression after TACE would benefit from
repeat TACE.
Methods
The records of 27 patients undergoing repeat TACE for radiologic or symptomatic progression after TACE for metastatic carcinoid
were reviewed and compared to 122 undergoing first TACE. Overall and progression-free survivals were estimated by the Kaplan–Meier
method.
Results
Mean disease-free interval after first TACE was 11.8 months. Radiologic response was observed in 61% compared to 82% after
first TACE (p = 0.058); hormone response in 64% compared to 80% (p = 0.159); and symptomatic response in 77% compared to 92% (p = 0.053). The complication rate after repeat TACE was lower than after first TACE (p = 0.03). Median overall survival was similar after repeat (28.1 months) and first TACE (33.3 months) (p = 0.53). Progression-free survival was shorter after repeat TACE but not significantly so. No factor examined could predict
survival after repeat TACE.
Conclusion
Repeat TACE for patients with hepatic carcinoid metastases failing first TACE or having evidence of disease progression is
safe and offers a viable treatment option.
Presented at the 48th Annual Meeting of The Society for Surgery of the Alimentary Tract, Washington, DC, May, 2007. 相似文献
110.
Cholangiocarcinomas (CC) frequently demonstrate lymphatic spread. We investigated lymph node (LN) counts after resection of
extrahepatic CC and survival based on the SEER 1973–2004 database. Out of 20,068 CC patients, 1,518 individuals were selected
based on M0 stage and at least one LN examined. Primary cancer sites included gallbladder (29%), extrahepatic bile ducts (26%),
and intrapancreatic/ampullary bile ducts (45%); 42% of patients were LN-positive. The median number of LNs examined was four
(range 1–39). Median survival was 37 months for LN-negative and 16 months for LN-positive cancers. Multivariate prognostic
variables were the number of positive LNs, primary site, age (all at p < 0.0001), gender (p = 0.002), size (p = 0.005), T category (p = 0.009), and total LN count (or number of negative LNs obtained, p = 0.01). The impact of total LN counts was seen in LN-negative (median survival, 1 vs 10 or more LNs examined: 27 vs 51 months,
p = 0.002) and LN-positive disease (10 vs 22 months, p < 0.0001). Survival prediction of extrahepatic CCs is strongly influenced by total LN counts and numbers of negative LNs
obtained. Although the resulting incremental benefit is small, dissection and examination of 10 or more LNs should be considered
for curative intent resections. 相似文献